From the Research
Effectiveness of Cefuroxime Axetil
- Cefuroxime axetil is effective against a wide range of bacteria, including those that cause upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI) 1, 2, 3.
- The drug has been shown to be effective in treating URTI, including otitis media, pharyngitis, and sinusitis, as well as LRTI, such as pneumonia and acute exacerbations of chronic bronchitis 2, 3, 4, 5.
- Cefuroxime axetil has been compared to other antibiotics, such as amoxicillin/clavulanic acid, and has been found to be equally effective in treating community-acquired pneumonia and other respiratory tract infections 2, 4.
Spectrum of Activity
- Cefuroxime axetil has a broad spectrum of activity against gram-positive and gram-negative bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis 1, 2, 3.
- The drug is also effective against beta-lactamase-positive respiratory pathogens, such as H. influenzae and M. catarrhalis 2, 3.
Clinical Efficacy
- Clinical trials have demonstrated the efficacy of cefuroxime axetil in treating URTI and LRTI, with satisfactory clinical outcomes achieved in 90-100% of patients 2, 3, 4, 5.
- The drug has also been shown to be effective in eradicating bacterial pathogens, with satisfactory bacteriological outcomes achieved in 90-95% of patients 2, 4.
Limitations
- There is no direct evidence on the effectiveness of cefuroxime axetil specifically for treating Mycoplasma pneumoniae upper respiratory tract infections 1, 2, 3, 4, 5.
- Mycoplasma pneumoniae is not mentioned as a susceptible organism in the provided studies, suggesting that cefuroxime axetil may not be effective against this particular pathogen 1, 2, 3, 4, 5.